News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
187,913 Results
Type
Article (18100)
Company Profile (17)
Press Release (169790)
Multimedia
Podcasts (33)
Webinars (11)
Section
Business (52350)
Career Advice (391)
Deals (8738)
Drug Delivery (69)
Drug Development (30935)
Employer Resources (41)
FDA (4946)
Job Trends (4604)
News (94891)
Policy (8532)
Tag
2027 Pharm Country Standard (1)
Academia (1047)
Accelerated approval (24)
Adcomms (18)
Allergies (80)
Alliances (12672)
ALS (92)
Alzheimer's disease (1285)
Antibody-drug conjugate (ADC) (231)
Approvals (5006)
Artificial intelligence (310)
Autoimmune disease (128)
Automation (16)
Bankruptcy (61)
Best Places to Work (3707)
BIOSECURE Act (8)
Biosimilars (67)
Biotechnology (11)
Bladder cancer (103)
Brain cancer (34)
Breast cancer (447)
Cancer (3063)
Cardiovascular disease (214)
Career advice (348)
Career pathing (24)
CAR-T (166)
CDC (24)
Celiac Disease (1)
Cell therapy (415)
Cervical cancer (32)
Clinical research (27259)
Collaboration (832)
Company closure (3)
Compensation (131)
Complete response letters (38)
COVID-19 (1437)
CRISPR (44)
C-suite (581)
Cystic fibrosis (69)
Data (3745)
Decentralized trials (1)
Denatured (5)
Depression (78)
Dermatology (39)
Diabetes (223)
Diagnostics (3224)
Digital health (18)
Diversity (4)
Diversity, equity & inclusion (13)
Drug discovery (139)
Drug pricing (108)
Drug shortages (16)
Duchenne muscular dystrophy (139)
Earnings (22748)
Editorial (47)
Employer branding (5)
Employer resources (40)
Events (22227)
Executive appointments (493)
FDA (6471)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (12)
Frontotemporal dementia (19)
Funding (746)
Gene editing (117)
Generative AI (28)
Gene therapy (392)
GLP-1 (521)
Government (1647)
Grass and pollen (3)
Guidances (175)
Healthcare (5325)
HIV (38)
Huntington's disease (33)
Idiopathic pulmonary fibrosis (1)
IgA nephropathy (49)
Immunology and inflammation (184)
Immuno-oncology (54)
Indications (80)
Infectious disease (1589)
Inflammatory bowel disease (70)
Inflation Reduction Act (6)
Influenza (54)
Intellectual property (103)
Interviews (83)
IPO (4265)
IRA (23)
Job creations (1045)
Job search strategy (262)
JPM (39)
Kidney cancer (13)
Labor market (37)
Layoffs (280)
Leadership (18)
Legal (1454)
Liver cancer (41)
Longevity (8)
Lung cancer (417)
Lymphoma (247)
Machine learning (38)
Management (14)
Manufacturing (398)
MASH (94)
Medical device (3384)
Medtech (3423)
Mergers & acquisitions (4849)
Metabolic disorders (675)
mRNA (109)
Multiple sclerosis (99)
NASH (13)
Neurodegenerative disease (271)
Neuropsychiatric disorders (60)
Neuroscience (2035)
Neurotech (1)
NextGen: Class of 2026 (1618)
Non-profit (1402)
Now hiring (6)
Obesity (358)
Opinion (183)
Ovarian cancer (98)
Pain (81)
Pancreatic cancer (163)
Parkinson's disease (197)
Partnered (15)
Patents (169)
Patient recruitment (294)
Peanut (25)
People (17022)
Pharmaceutical (3)
Pharmacy benefit managers (12)
Phase 1 (8620)
Phase 2 (12158)
Phase 3 (9597)
Pipeline (3980)
Policy (140)
Postmarket research (711)
Preclinical (2875)
Press Release (28)
Prostate cancer (160)
Psychedelics (25)
Radiopharmaceuticals (137)
Rare diseases (552)
Real estate (1432)
Recruiting (14)
Regulatory (7628)
Reports (16)
Research institute (1019)
Resumes & cover letters (44)
Rett syndrome (24)
RNA editing (14)
RSV (47)
Schizophrenia (88)
Series A (135)
Series B (87)
Service/supplier (1)
Sickle cell disease (47)
Special edition (10)
Spinal muscular atrophy (101)
Sponsored (20)
Startups (1519)
Stomach cancer (10)
Supply chain (33)
Tariffs (60)
The Weekly (27)
Vaccines (512)
Venture capital (81)
Weight loss (266)
Women's health (51)
Worklife (7)
Date
Last 7 days (392)
Last 30 days (1242)
Last 365 days (11831)
2026 (4547)
2025 (11427)
2024 (11903)
2023 (13196)
2022 (16112)
2021 (16892)
2020 (15866)
2019 (12180)
2018 (9472)
2017 (9517)
2016 (8514)
2015 (9586)
2014 (6452)
2013 (4774)
2012 (5213)
2011 (5505)
2010 (4806)
Location
Africa (220)
Alabama (25)
Alaska (1)
Arizona (75)
Arkansas (4)
Asia (11748)
Australia (2350)
California (4656)
Canada (1172)
China (548)
Colorado (161)
Connecticut (186)
Delaware (158)
Europe (28988)
Florida (615)
Georgia (111)
Idaho (8)
Illinois (323)
India (36)
Indiana (202)
Iowa (7)
Japan (230)
Kansas (43)
Kentucky (10)
Louisiana (11)
Maine (16)
Maryland (467)
Massachusetts (3477)
Michigan (86)
Minnesota (155)
Mississippi (2)
Missouri (43)
Montana (7)
Nebraska (9)
Nevada (46)
New Hampshire (42)
New Jersey (1269)
New Mexico (13)
New York (1308)
North Carolina (446)
Northern California (2375)
Ohio (98)
Oklahoma (9)
Oregon (13)
Pennsylvania (798)
Puerto Rico (10)
Rhode Island (10)
South America (244)
South Carolina (13)
Southern California (1860)
Tennessee (45)
Texas (905)
United States (16000)
Utah (151)
Virginia (83)
Washington D.C. (26)
Washington State (359)
West Virginia (1)
Wisconsin (55)
187,913 Results for "earli".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Lung cancer
Summit shares descend as PD-1/VEGF asset misses early survival mark
Summit Therapeutics planned an early interim progression-free survival readout for HARMONi-3 in the hope of enabling earlier regulatory engagement—but the early analysis delivered disappointment for the company and shareholders.
May 4, 2026
·
2 min read
·
Tristan Manalac
Insights
Biotech angels lean into deeper diligence and disciplined early bets
Angel investors are raising the bar with tighter criteria, backing strong teams, realistic markets and clear paths to exit while applying deeper, domain-specific diligence to early stage bets.
April 29, 2026
·
4 min read
·
Jennifer C. Smith-Parker
Pipeline
Pfizer culls early PD-L1 asset after series of clinical wins, deals in cancer
Pfizer’s decision to cut its early-stage cancer asset was due to “strategic business reasons” and not driven by safety or efficacy concerns.
April 24, 2026
·
2 min read
·
Tristan Manalac
Earnings
With growth curve trending up, Biogen looks to early-stage assets for ‘next generation’
Biogen’s growth was expected to stay flat through the 2030s. A key acquisition and busy late-stage pipeline have relieved the pressure and cleared the way for some early-stage bets, CEO Chris Viehbacher said Wednesday.
April 29, 2026
·
3 min read
·
Annalee Armstrong
Funding
AI-Focused Fund Breakout Raises $114M To Support Early-Stage Biotechs
Breakout Ventures’ focus on early-stage companies stands out as more and more investors elect to save their dollars for derisked assets.
March 10, 2026
·
2 min read
·
Tristan Manalac
Pipeline
Novartis Cuts 6 Early Cancer Candidates, Adds 2 to Refine Oncology Strategy
Despite the Phase 1 cull, CEO Vas Narasimhan on Wednesday maintained that Novartis continues to invest in its early-stage pipeline, looking for deals in the “sub-$2-billion range.”
February 5, 2026
·
2 min read
·
Tristan Manalac
Earnings
Novartis Sticks With M&A Strategy of Building Early Pipeline, Searching for Near-Launches
Novartis will still be on the lookout for early-stage deals under $2 billion, and later-stage agreements around a product that could reach the market within five years, CEO Vas Narasimhan said Wednesday.
February 4, 2026
·
2 min read
·
Tristan Manalac
Venture capital
Early-Stage Biotechs Feel the Squeeze as Funding Favors Derisked Assets: JPM
Heightened diligence standards and longer decision timelines for early-stage startups slowed venture activity last year, J.P. Morgan found in a report published ahead of the bank’s annual healthcare conference in San Francisco.
January 12, 2026
·
2 min read
·
Nick Paul Taylor
Opinion
Even Early Stage Biotechs Can’t Ignore Tariffs
Early decisions about manufacturing and supply chains could prove costly as a company reaches the commercial stage.
December 3, 2025
·
4 min read
·
Josh Medow
Press Releases
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development
May 7, 2026
·
2 min read
1 of 18,792
Next
